Neuland Laboratories Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Neuland Laboratories Ltd is ₹ 14998 as of 30 Apr 15:30 . The P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 yearsThe P/E Ratio of OneSource Specialty Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 yearsThe Market Cap of OneSource Specialty Pharma Ltd changed from ₹ 20003 crore on March 2025 to ₹ 20003 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Neuland Laboratories Ltd for the Dec '25 is ₹ 447.76 crore as compare to the Sep '25 revenue of ₹ 516.07 crore. This represent the decline of -13.24% The revenue of OneSource Specialty Pharma Ltd for the Dec '25 is ₹ 294.97 crore as compare to the Sep '25 revenue of ₹ 378.8 crore. This represent the decline of -22.13% The ebitda of Neuland Laboratories Ltd for the Dec '25 is ₹ 85.19 crore as compare to the Sep '25 ebitda of ₹ 157.35 crore. This represent the decline of -45.86% The ebitda of OneSource Specialty Pharma Ltd for the Dec '25 is ₹ 14.86 crore as compare to the Sep '25 ebitda of ₹ 109.53 crore. This represent the decline of -86.43% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 40.57 crore over 7 quarters. This represents a CAGR of -39.54% The net profit of OneSource Specialty Pharma Ltd changed from ₹ -5.55 crore to ₹ -88.7 crore over 7 quarters. This represents a CAGR of 387.29% The Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 yearsThe Dividend Payout of OneSource Specialty Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

About OneSource Specialty Pharma Ltd

Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore.
The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies.
The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,.
Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.

FAQs for the comparison of Neuland Laboratories Ltd and OneSource Specialty Pharma Ltd

Which company has a larger market capitalization, Neuland Laboratories Ltd or OneSource Specialty Pharma Ltd?

Market cap of Neuland Laboratories Ltd is 19,243 Cr while Market cap of OneSource Specialty Pharma Ltd is 19,938 Cr

What are the key factors driving the stock performance of Neuland Laboratories Ltd and OneSource Specialty Pharma Ltd?

The stock performance of Neuland Laboratories Ltd and OneSource Specialty Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Neuland Laboratories Ltd and OneSource Specialty Pharma Ltd?

As of May 4, 2026, the Neuland Laboratories Ltd stock price is INR ₹14998.7. On the other hand, OneSource Specialty Pharma Ltd stock price is INR ₹1739.2.

How do dividend payouts of Neuland Laboratories Ltd and OneSource Specialty Pharma Ltd compare?

To compare the dividend payouts of Neuland Laboratories Ltd and OneSource Specialty Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.